Review
Similar Products
|
InvivoGen
sting agonist 2 3 cgamp Sting Agonist 2 3 Cgamp, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sting agonist 2 3 cgamp/product/InvivoGen Average 96 stars, based on 1 article reviews
sting agonist 2 3 cgamp - by Bioz Stars,
2026-03
96/100 stars
|
Buy from Supplier |
|
MedChemExpress
sting inhibitor h 151 Sting Inhibitor H 151, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sting inhibitor h 151/product/MedChemExpress Average 96 stars, based on 1 article reviews
sting inhibitor h 151 - by Bioz Stars,
2026-03
96/100 stars
|
Buy from Supplier |
|
MedChemExpress
cgas sting signaling Cgas Sting Signaling, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cgas sting signaling/product/MedChemExpress Average 94 stars, based on 1 article reviews
cgas sting signaling - by Bioz Stars,
2026-03
94/100 stars
|
Buy from Supplier |
|
MedChemExpress
sting agonist adu s100 ammonium salt  Sting Agonist Adu S100 Ammonium Salt, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sting agonist adu s100 ammonium salt/product/MedChemExpress Average 93 stars, based on 1 article reviews
sting agonist adu s100 ammonium salt - by Bioz Stars,
2026-03
93/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Cancer Immunology, Immunotherapy : CII
Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms
doi: 10.1007/s00262-026-04329-8
Figure Lengend Snippet: Dynamics of immune cell subsets in response to agonist stimulation. A Schematic of the experimental workflow. Immune profiling by flow cytometry was performed 48 h after a single intratumoral injection of PRR agonists. B Percentage of CD45 + leukocytes among live cells following intratumoral administration of different agonists: TLR3 agonist poly IC (25 µg/tumor), TLR7 agonist imiquimod hydrochloride (25 µg/tumor), TLR8 agonist TL8-506 (10 µg/tumor), TLR9 agonist CpG ODN 2395 (50 µg/tumor), STING agonist ADU-S100 ammonium salt (25 µg/tumor), NOD1 agonist Tri-DAP (10 µg/tumor), and NOD2 agonist murabutide (5 µg/tumor). C Proportion of cDCs within the CD45 + population. D Percentage of ZsGreen + cells among DCs. E Proportion of macrophages within the CD45 + population. F Percentage of ZsGreen + cells among macrophages. G Proportion of CD8 + T cells within the CD45 + compartment. H Proportion of cCD4 + T cells within the CD45 + compartment. I Proportion of Tregs within the CD45 + compartment, pooled from two independent experiments. J Ratio of cCD4 + T cells to Tregs. (K) Ratio of CD8 + T cells to Tregs. Data represent the mean ± SEM ( n = 8 mice per group). Statistical comparisons were performed using one-way ANOVA. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
Article Snippet: When tumors reached approximately 200 mm 3 , PRR agonists were administered via intratumoral injection at the following doses: TLR3 agonist poly(I:C) (Sigma-Aldrich, #42,424–50-0; 25 μg/tumor); TLR7 agonist imiquimod hydrochloride (MedChemExpress, #HY-B0180A; 25 μg/tumor); TLR8 agonist TL8-506 (InvivoGen, #tlrl-tl8506; 10 μg/tumor); TLR8 agonist motolimod (MedChemExpress, #HY-13773; 50 μg/tumor); TLR9 agonist CpG ODN 2395 (Class C) (InvivoGen, #tlrl-2395–1; 50 μg/tumor);
Techniques: Flow Cytometry, Injection